Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia

David W. Volk, Stephen M. Eggan, Andrew Horti, Dean Foster Wong, David A. Lewis

Research output: Contribution to journalArticle

Abstract

The deleterious effects of cannabis use in schizophrenia have been linked, in part, to underlying disturbances in endogenous cannabinoid signaling in the prefrontal cortex. However, while receptor autoradiography studies of the primary cannabinoid receptor (CB1R) have consistently found higher CB1R binding in the prefrontal cortex in schizophrenia, deficits in CB1R mRNA levels and protein immunoreactivity have also been reported in the illness. To investigate this apparent discrepancy, we quantified CB1R binding using receptor autoradiography with the selective CB1R ligand [3H]-OMAR in the prefrontal cortex of 21 subjects with schizophrenia who were previously found to have lower levels of both CB1R mRNA using in situ hybridization and CB1R protein using radioimmunocytochemistry relative to matched healthy comparison subjects. We observed higher levels of [3H]-OMAR binding in the prefrontal cortex of schizophrenia subjects that did not appear to be attributable to psychotropic medications or substance abuse. The combination of lower levels of CB1R mRNA and immunoreactivity with higher CB1R receptor binding may reflect 1) altered trafficking of the receptor resulting in higher levels of membrane-bound CB1R or 2) higher CB1R affinity. In either case, greater CB1R receptor availability may contribute to the increased susceptibility of schizophrenia subjects to the deleterious effects of cannabis use.

Original languageEnglish (US)
Pages (from-to)124-129
Number of pages6
JournalSchizophrenia Research
Volume159
Issue number1
DOIs
StatePublished - Oct 1 2014

Fingerprint

Cannabinoid Receptors
Schizophrenia
Prefrontal Cortex
Cannabis
Proteins
Autoradiography
Messenger RNA
Cannabinoids
Substance-Related Disorders
In Situ Hybridization
Healthy Volunteers
Ligands
Membranes

Keywords

  • Cannabinoid
  • Cannabis
  • CB1R
  • Marijuana
  • PET
  • Prefrontal cortex
  • Radioligand
  • Rimonabant
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. / Volk, David W.; Eggan, Stephen M.; Horti, Andrew; Wong, Dean Foster; Lewis, David A.

In: Schizophrenia Research, Vol. 159, No. 1, 01.10.2014, p. 124-129.

Research output: Contribution to journalArticle

@article{f94618f4400445fba937b3cd4e097656,
title = "Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia",
abstract = "The deleterious effects of cannabis use in schizophrenia have been linked, in part, to underlying disturbances in endogenous cannabinoid signaling in the prefrontal cortex. However, while receptor autoradiography studies of the primary cannabinoid receptor (CB1R) have consistently found higher CB1R binding in the prefrontal cortex in schizophrenia, deficits in CB1R mRNA levels and protein immunoreactivity have also been reported in the illness. To investigate this apparent discrepancy, we quantified CB1R binding using receptor autoradiography with the selective CB1R ligand [3H]-OMAR in the prefrontal cortex of 21 subjects with schizophrenia who were previously found to have lower levels of both CB1R mRNA using in situ hybridization and CB1R protein using radioimmunocytochemistry relative to matched healthy comparison subjects. We observed higher levels of [3H]-OMAR binding in the prefrontal cortex of schizophrenia subjects that did not appear to be attributable to psychotropic medications or substance abuse. The combination of lower levels of CB1R mRNA and immunoreactivity with higher CB1R receptor binding may reflect 1) altered trafficking of the receptor resulting in higher levels of membrane-bound CB1R or 2) higher CB1R affinity. In either case, greater CB1R receptor availability may contribute to the increased susceptibility of schizophrenia subjects to the deleterious effects of cannabis use.",
keywords = "Cannabinoid, Cannabis, CB1R, Marijuana, PET, Prefrontal cortex, Radioligand, Rimonabant, Schizophrenia",
author = "Volk, {David W.} and Eggan, {Stephen M.} and Andrew Horti and Wong, {Dean Foster} and Lewis, {David A.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.schres.2014.07.017",
language = "English (US)",
volume = "159",
pages = "124--129",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia

AU - Volk, David W.

AU - Eggan, Stephen M.

AU - Horti, Andrew

AU - Wong, Dean Foster

AU - Lewis, David A.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - The deleterious effects of cannabis use in schizophrenia have been linked, in part, to underlying disturbances in endogenous cannabinoid signaling in the prefrontal cortex. However, while receptor autoradiography studies of the primary cannabinoid receptor (CB1R) have consistently found higher CB1R binding in the prefrontal cortex in schizophrenia, deficits in CB1R mRNA levels and protein immunoreactivity have also been reported in the illness. To investigate this apparent discrepancy, we quantified CB1R binding using receptor autoradiography with the selective CB1R ligand [3H]-OMAR in the prefrontal cortex of 21 subjects with schizophrenia who were previously found to have lower levels of both CB1R mRNA using in situ hybridization and CB1R protein using radioimmunocytochemistry relative to matched healthy comparison subjects. We observed higher levels of [3H]-OMAR binding in the prefrontal cortex of schizophrenia subjects that did not appear to be attributable to psychotropic medications or substance abuse. The combination of lower levels of CB1R mRNA and immunoreactivity with higher CB1R receptor binding may reflect 1) altered trafficking of the receptor resulting in higher levels of membrane-bound CB1R or 2) higher CB1R affinity. In either case, greater CB1R receptor availability may contribute to the increased susceptibility of schizophrenia subjects to the deleterious effects of cannabis use.

AB - The deleterious effects of cannabis use in schizophrenia have been linked, in part, to underlying disturbances in endogenous cannabinoid signaling in the prefrontal cortex. However, while receptor autoradiography studies of the primary cannabinoid receptor (CB1R) have consistently found higher CB1R binding in the prefrontal cortex in schizophrenia, deficits in CB1R mRNA levels and protein immunoreactivity have also been reported in the illness. To investigate this apparent discrepancy, we quantified CB1R binding using receptor autoradiography with the selective CB1R ligand [3H]-OMAR in the prefrontal cortex of 21 subjects with schizophrenia who were previously found to have lower levels of both CB1R mRNA using in situ hybridization and CB1R protein using radioimmunocytochemistry relative to matched healthy comparison subjects. We observed higher levels of [3H]-OMAR binding in the prefrontal cortex of schizophrenia subjects that did not appear to be attributable to psychotropic medications or substance abuse. The combination of lower levels of CB1R mRNA and immunoreactivity with higher CB1R receptor binding may reflect 1) altered trafficking of the receptor resulting in higher levels of membrane-bound CB1R or 2) higher CB1R affinity. In either case, greater CB1R receptor availability may contribute to the increased susceptibility of schizophrenia subjects to the deleterious effects of cannabis use.

KW - Cannabinoid

KW - Cannabis

KW - CB1R

KW - Marijuana

KW - PET

KW - Prefrontal cortex

KW - Radioligand

KW - Rimonabant

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84908048904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908048904&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2014.07.017

DO - 10.1016/j.schres.2014.07.017

M3 - Article

C2 - 25107849

AN - SCOPUS:84908048904

VL - 159

SP - 124

EP - 129

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -